Retatrutide and Testosterone Interaction: Safety, Monitoring, and What Clinicians Should Know

Why This Combination Is Becoming More Common

Men with obesity frequently present with secondary hypogonadism. Low testosterone and excess adiposity feed each other in a well-documented cycle: visceral fat increases aromatase activity, converting testosterone to estradiol, which suppresses the hypothalamic-pituitary-gonadal axis and drives testosterone levels lower [1]. The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism acknowledges obesity as a reversible cause of low testosterone and recommends weight loss as a first-line intervention before initiating testosterone replacement [2].

Retatrutide, Eli Lilly's investigational triple-hormone-receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, produced striking weight loss results in the phase 2 trial published in The New England Journal of Medicine. At the 12 mg dose, participants lost a mean of 24.2% of body weight over 48 weeks (N=338 total across dose groups) [3]. That degree of fat loss could theoretically restore endogenous testosterone production. But many men begin testosterone replacement therapy (TRT) before or during GLP-1 receptor agonist treatment, creating a combination that clinicians need to evaluate for safety.

Pharmacokinetic Assessment: No CYP or Transporter Conflict Expected

Retatrutide is a 39-amino-acid peptide. Like other incretin-based therapies, it undergoes proteolytic degradation rather than hepatic cytochrome P450 metabolism [4]. Testosterone, whether administered as cypionate, enanthate, or transdermal gel, is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19 [5]. Because retatrutide does not inhibit, induce, or serve as a substrate for these CYP isoenzymes, a direct pharmacokinetic interaction is not expected.

This matters. The absence of CYP-mediated interference means testosterone serum concentrations should not change meaningfully when retatrutide is added. A similar pharmacokinetic profile has been confirmed for semaglutide and tirzepatide, both of which showed no clinically significant effect on the pharmacokinetics of co-administered drugs metabolized by major CYP enzymes in dedicated interaction studies [6].

One caveat deserves attention. GLP-1 receptor agonists slow gastric emptying, which can delay the absorption of oral medications [7]. This is irrelevant for injectable testosterone (cypionate or enanthate) but could theoretically affect oral testosterone undecanoate (Jatenzo), which depends on intestinal lymphatic absorption with a fatty meal. No formal interaction study between any GLP-1 receptor agonist and oral testosterone undecanoate has been published. Patients using Jatenzo alongside retatrutide should be monitored for subtherapeutic testosterone levels, particularly during the dose-escalation phase when GLP-1-mediated gastric slowing is most pronounced.

Polycythemia: The Central Pharmacodynamic Risk

This is the risk that warrants the most clinical attention. Testosterone stimulates erythropoiesis through direct action on erythroid progenitor cells and by suppressing hepcidin, the master regulator of iron availability [8]. The FDA label for testosterone cypionate carries a warning for polycythemia, defined as hematocrit exceeding 54%, and the Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months after initiation, and annually thereafter [2].

Retatrutide's effect on hematocrit has not been independently characterized in published trial data. GLP-1 receptor agonists as a class have not been associated with erythrocytosis. Glucagon receptor agonism, the third target in retatrutide's triple mechanism, has theoretical implications for fluid balance and hemoconcentration. Glucagon promotes hepatic glycogenolysis and has mild diuretic properties; sustained activation could raise hematocrit through plasma volume contraction rather than true erythrocytosis [9]. The distinction matters clinically because hemoconcentration-driven hematocrit elevation responds to hydration, while testosterone-driven erythrocytosis requires dose reduction or phlebotomy.

When both mechanisms operate simultaneously, hematocrit can climb faster than either agent alone would produce. The 2018 Endocrine Society guideline states: "If hematocrit exceeds 54%, stop testosterone therapy until hematocrit decreases to a safe level; evaluate the patient for hypoxia and sleep apnea; reinitiate therapy with a reduced dose" [2]. For patients also receiving retatrutide, clinicians should check CBCs every 3 months during the first year of combination use rather than relying on the standard 6-month interval.

Lipid Effects: Opposing Actions That May Not Cancel Out

Testosterone and incretin-based therapies push lipid panels in different directions, and the net effect is difficult to predict without patient-specific monitoring.

Exogenous testosterone, particularly at supraphysiologic doses, tends to lower HDL cholesterol. A meta-analysis of 59 randomized controlled trials found that testosterone therapy reduced HDL by a weighted mean of 0.49 mmol/L (approximately 19 mg/dL) across studies, with the effect most pronounced in oral formulations [10]. LDL changes were inconsistent across trials, and triglyceride effects were generally neutral.

Retatrutide's phase 2 data, by contrast, showed improvements in multiple cardiometabolic markers. The Jastreboff et al. NEJM publication reported that the 12 mg dose group experienced significant reductions in waist circumference, fasting glucose, and HbA1c [3]. While detailed lipid subgroup analyses from the retatrutide phase 2 trial have not been fully published in a standalone lipid-focused paper, the broader class of GLP-1 receptor agonists has demonstrated consistent LDL and triglyceride reductions. The STEP-1 trial (semaglutide 2.4 mg, N=1,961) showed a 3.1% reduction in LDL cholesterol and a 12.4% reduction in triglycerides compared to placebo at 68 weeks [11].

The practical concern is that testosterone's HDL-lowering effect may partially offset the lipid benefits gained from retatrutide-driven weight loss. Clinicians should obtain a fasting lipid panel at baseline, at 12 weeks, and every 6 months thereafter when both agents are used concurrently.

Cardiovascular Risk Signals: What the Data Actually Show

Both drug classes carry cardiovascular risk considerations, though the evidence points in different directions.

For testosterone, the TRAVERSE trial (N=5,246) provided the first adequately powered cardiovascular safety data. Published in The New England Journal of Medicine in 2023, TRAVERSE demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.73; 95% CI 0.52 to 1.01 for the non-inferiority comparison) [12]. The FDA subsequently updated testosterone labeling to reflect these findings, though the boxed warning about cardiovascular risk was retained pending longer follow-up.

For GLP-1 receptor agonists, the SELECT trial (semaglutide 2.4 mg, N=17,604) demonstrated a 20% reduction in MACE in adults with overweight or obesity and established cardiovascular disease but without diabetes [13]. Retatrutide's cardiovascular outcomes data do not yet exist. The phase 3 TRIUMPH program is ongoing, and cardiovascular event data will not be available for several years [14].

Dr. Ania Jastreboff, the lead investigator of the retatrutide phase 2 trial at Yale, noted in comments accompanying the NEJM publication: "The magnitude of weight loss with retatrutide exceeds what we have seen with dual-receptor agonists, but we need dedicated cardiovascular outcomes trials before we can make claims about cardioprotection" [3].

The combination of testosterone (CV-neutral per TRAVERSE) and a GLP-1-class agent (CV-protective per SELECT) does not suggest additive cardiovascular harm based on available evidence. Polycythemia remains the primary vascular risk vector, as elevated hematocrit independently increases thrombotic event risk [15].

Body Composition: How Weight Loss Affects Testosterone Levels

Aggressive weight loss raises an important question for men on concurrent TRT: does retatrutide-driven fat loss restore endogenous testosterone production enough to make exogenous therapy unnecessary?

The European Male Ageing Study (EMAS), a population-based cohort of 2,736 men, found that a 15% or greater reduction in body weight was associated with a mean increase in total testosterone of 2.9 nmol/L (approximately 84 ng/dL) [16]. With retatrutide producing 24.2% mean weight loss at the 12 mg dose [3], some men with obesity-related secondary hypogonadism could see endogenous testosterone recover into the normal range.

The clinical implication is straightforward. Men who began TRT primarily for obesity-related hypogonadism should have their testosterone levels reassessed after 6 months of retatrutide therapy. If total testosterone exceeds 400 ng/dL while on both agents, a supervised taper of exogenous testosterone may be appropriate. The Endocrine Society guideline recommends against indefinite testosterone therapy in men whose hypogonadism is attributable to a reversible cause [2].

For men with primary hypogonadism (testicular failure, Klinefelter syndrome, bilateral orchiectomy), weight loss will not restore endogenous production, and TRT should continue regardless of retatrutide use.

Lean Mass Preservation During Rapid Weight Loss

A legitimate concern with any high-magnitude weight loss intervention is the loss of lean body mass alongside fat. GLP-1 receptor agonists, including semaglutide, have been shown to produce approximately 40% lean mass loss as a proportion of total weight lost in body composition substudies [17]. Testosterone therapy may partially counteract this effect through its anabolic properties.

A 2019 randomized trial of testosterone versus placebo in 100 men with obesity undergoing a very-low-calorie diet found that testosterone-treated men preserved 1.2 kg more lean mass over 56 weeks compared to placebo (P=0.004) [18]. While this study did not involve GLP-1 receptor agonists, the principle applies: exogenous testosterone provides an anabolic signal that opposes the catabolic drive of a sustained caloric deficit.

For male patients taking retatrutide who are concerned about muscle loss, concurrent testosterone therapy (assuming an appropriate clinical indication exists) may offer a lean-mass-preserving benefit. Resistance training remains the most evidence-based intervention for lean mass preservation during weight loss and should be recommended to all patients regardless of pharmacotherapy [19].

Monitoring Protocol for the Combination

No published guideline addresses the specific combination of a triple-receptor agonist and testosterone. The following protocol synthesizes Endocrine Society testosterone monitoring recommendations [2] with standard GLP-1 receptor agonist safety parameters.

Baseline (before starting the combination):

• CBC with hematocrit
• Fasting lipid panel
• Total and free testosterone, LH, FSH
• PSA (men over 40)
• Comprehensive metabolic panel including liver function tests
• HbA1c and fasting glucose
• Blood pressure

At 6 and 12 weeks:

• CBC with hematocrit (to detect early polycythemia)
• Renal function (retatrutide dose escalation period; dehydration risk)
• Total testosterone trough level

Every 3 months for the first year:

• CBC with hematocrit
• Fasting lipid panel at 3 and 6 months, then every 6 months
• Total testosterone trough level

Annually thereafter:

• Full panel as above
• PSA
• Reassess need for testosterone therapy based on body weight changes

When to Adjust or Discontinue One Agent

Three clinical triggers should prompt intervention:

Hematocrit above 50% but below 54%. Increase monitoring frequency to monthly. Ensure adequate hydration. Consider reducing testosterone dose by 20 to 25%. Do not adjust retatrutide.

Hematocrit at or above 54%. Discontinue testosterone per Endocrine Society guidance [2]. Rule out obstructive sleep apnea (which independently raises hematocrit and is common in obesity). Therapeutic phlebotomy if symptomatic. Retatrutide can continue; monitor hematocrit monthly until below 50%.

Persistent nausea or vomiting from retatrutide affecting testosterone gel absorption. GI side effects occurred in 16 to 34% of participants across retatrutide dose groups in the phase 2 trial [3]. If a patient uses transdermal testosterone and experiences protracted vomiting (not relevant for absorption) or if oral testosterone undecanoate is used and GI transit is severely disrupted, switch to injectable testosterone to bypass absorption variability.

The American Urological Association notes in its 2018 testosterone guideline: "Clinicians should adjust the testosterone dose, formulation, or administration frequency to maintain hematocrit below 54%" [20].

The Investigational Status of Retatrutide

Retatrutide is not FDA-approved as of May 2026. All clinical use occurs within the phase 3 TRIUMPH trial framework or through compounding pathways whose regulatory status remains uncertain. Clinicians prescribing testosterone to patients who are also enrolled in a retatrutide trial should coordinate with the trial site's principal investigator, as concomitant testosterone use may be a protocol inclusion/exclusion criterion.

Prescribers considering compounded retatrutide should be aware that the FDA issued guidance in 2024 regarding GLP-1 receptor agonist compounding, and the regulatory environment continues to evolve [21]. The safety monitoring recommendations in this article apply regardless of how retatrutide is obtained, but patients should understand that combination safety data are limited to mechanistic inference and class-level evidence rather than dedicated interaction studies.